Gastroenterology
Latest news
416 articles · 20 / page
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study
The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.
Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review
This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver healt
Time-Restricted Eating as a Promising Approach for Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence from a Randomized Controlled Trial
A 16-week RCT demonstrates that time-restricted eating significantly reduces hepatic steatosis in MASLD, offering comparable metabolic benefits to calorie restriction without adverse events.
Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival
This comprehensive analysis reveals that progression-free survival moderately correlates with overall survival in advanced biliary tract cancer, while objective response and disease control rates show poor correlation, underscoring the need
Rifaximin’s Role in Severe Cirrhosis with Ascites: Insights from a Randomized Controlled Trial
A randomized trial showed rifaximin does not improve 12-month survival or reduce complications in severe cirrhosis with ascites, but better adherence may decrease liver-related events.
Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications
The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding risk.
Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications
The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding risk.
Patient-Derived Liver Organoids: A Breakthrough for Precision Modeling and Treatment of Alcohol-Related Liver Disease
Patient-derived liver organoids from needle biopsies replicate liver epithelial diversity and disease stage features, enabling personalized modeling and therapeutic testing in alcohol-related liver disease.
Targeting Xanthine Oxidoreductase: A New Frontier to Overcome EGFR TKI Resistance in Intrahepatic Cholangiocarcinoma
Xanthine oxidoreductase (XOR) drives resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma by stabilizing EGFR and enhancing DNA repair. Targeting XOR sensitizes tumors to EGFR TKIs and suppresses cancer progressi
Proteogenomic Insights into Personalized Adjuvant Chemotherapy for Extrahepatic Cholangiocarcinoma
Comprehensive proteogenomic profiling in resected extrahepatic cholangiocarcinoma reveals predictive biomarkers for tailoring adjuvant chemotherapy, offering a precision medicine approach to improve patient outcomes.
Innovative TCR T-Cell Therapy Shows Promise in Advanced Hepatocellular and Gastric Hepatoid Carcinoma
A phase I trial reveals that ADP-A2AFP TCR T-cell therapy, targeting AFP-expressing advanced hepatocellular carcinoma and gastric hepatoid carcinoma, is safe and exhibits early antitumor activity in patients refractory to conventional treat
Unraveling Non-Acute Decompensation in Cirrhosis: A Distinct Clinical and Pathophysiological Entity with Prognostic Implications
Non-acute decompensation of cirrhosis (NAD) represents a distinct clinical state characterized by elevated cell death markers and moderate prognosis. Identifying predictors such as ascites severity and biomarkers Gasdermin-D and RIPK3 may g
RIPK3 as a Prognostic Biomarker in Acute Decompensation of Cirrhosis: Advancing Risk Stratification and Therapeutic Targeting
RIPK3-associated necroptosis critically drives organ failure and mortality in acute decompensation and ACLF, with its plasma levels robustly predicting outcomes and improving prognostic models to guide personalized therapies.
Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis
Claudin-1 is upregulated in primary sclerosing cholangitis (PSC), promoting biliary fibrosis and cholestasis. Preclinical models show that Claudin-1-specific monoclonal antibodies reduce liver injury and fibrosis, highlighting a promising t
Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts
Hypertension independently worsens clinical outcomes and liver fibrosis progression in MASLD, highlighting the need for integrated cardiovascular and hepatic care.
Unveiling the Molecular Link Between Alcohol and HBV-Driven Liver Cancer: The Role of ATF4/LPLA2-Mediated BMP Metabolism
Chronic alcohol intake exacerbates HBV-induced hepatocellular carcinoma by activating the ATF4/LPLA2 pathway, promoting BMP metabolism and MAPK/ERK signaling, identifying LPLA2 as a potential therapeutic target and prognostic marker.
Elevated Risk of Alcohol-Related Liver Disease and Mortality in Patients Undergoing Treatment for Alcohol Use Disorder: Insights from a Nationwide Danish Cohort
This study quantifies the heightened risk of alcohol-related liver disease, cancer, cardiovascular mortality, and all-cause death among individuals receiving treatment for alcohol use disorder compared to the general population, emphasizing
Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial
The Phase II INTEGRIS-PSC trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, is well tolerated in PSC patients with liver fibrosis and shows potential to attenuate fibrotic progression, supporting integrin-targeted th
Innovative Extracorporeal Therapy Combining HLA-Depleted Liver Organoids and Granulocyte-Monocyte Apheresis for Reversal of Acute Liver Failure
The UTOpiA system, integrating HLA-depleted iPSC-derived liver organoids with granulocyte-monocyte apheresis, significantly improves survival and liver regeneration in acute-on-chronic and acute liver failure rat models, representing a prom
Long-Term Real-World Effectiveness, Safety, and Liver Stiffness Changes with Obeticholic Acid in Primary Biliary Cholangitis
This study confirms the sustained effectiveness and safety of obeticholic acid (OCA) in primary biliary cholangitis (PBC) over a 2-year median follow-up, highlighting its impact on liver stiffness and fibrosis progression, especially in bio
Browse by specialty
Open language-specific specialty feeds and department pages.